Integer (NYSE:ITGR) Stock Rating Lowered by Oppenheimer

Integer (NYSE:ITGR) was downgraded by equities research analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a research note issued on Friday,Finviz reports.

Other analysts have also issued reports about the company. Piper Sandler reiterated an “overweight” rating and set a $140.00 price target (up from $125.00) on shares of Integer in a report on Friday, October 25th. KeyCorp lifted their price target on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Truist Financial lifted their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Wells Fargo & Company reiterated an “overweight” rating and set a $160.00 price target on shares of Integer in a report on Tuesday, December 3rd. Finally, Citigroup lifted their price target on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $146.56.

Integer Stock Down 5.1 %

Shares of NYSE:ITGR opened at $135.91 on Friday. Integer has a 52-week low of $97.49 and a 52-week high of $146.36. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.09 and a current ratio of 3.28. The business’s 50 day simple moving average is $137.98 and its two-hundred day simple moving average is $132.28. The firm has a market cap of $4.56 billion, a P/E ratio of 41.95, a PEG ratio of 1.82 and a beta of 1.13.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.70% and a return on equity of 11.63%. As a group, research analysts forecast that Integer will post 5.33 EPS for the current fiscal year.

Institutional Trading of Integer

A number of hedge funds and other institutional investors have recently made changes to their positions in ITGR. Creative Planning raised its stake in shares of Integer by 22.2% during the 3rd quarter. Creative Planning now owns 9,077 shares of the medical equipment provider’s stock valued at $1,180,000 after purchasing an additional 1,650 shares during the period. First Trust Direct Indexing L.P. bought a new stake in shares of Integer during the 3rd quarter valued at $215,000. Congress Asset Management Co. raised its stake in shares of Integer by 3.9% during the 3rd quarter. Congress Asset Management Co. now owns 488,785 shares of the medical equipment provider’s stock valued at $63,542,000 after purchasing an additional 18,303 shares during the period. New York State Common Retirement Fund raised its stake in shares of Integer by 1.0% during the 3rd quarter. New York State Common Retirement Fund now owns 192,411 shares of the medical equipment provider’s stock valued at $25,013,000 after purchasing an additional 1,820 shares during the period. Finally, James Investment Research Inc. increased its stake in Integer by 7.2% in the 3rd quarter. James Investment Research Inc. now owns 12,290 shares of the medical equipment provider’s stock worth $1,598,000 after acquiring an additional 824 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.